How does DADA2 present? Ten studies provided data on a total 225 patients 1) skin findings 2) fever 3) stroke 4) cytopenias @RheumNow #ACR25 Abst 1615 https://t.co/xZuTk6YFdJ

• https://x.com/Dr_Brian_MD/status/1982938644047446051/photo/1

PET and histologic discordance in aortitis Of 5 aortitis patients who had PET/CT prior to aortic surgery with path, only 1 showed concordance (neg PET, neg biopsy) 4/5 patients had inflammatory biopsy with neg PET Small # but PET is not perfect! @RheumNow #ACR25 Abst 1620

ACR2025 Day 2 Recap https://t.co/TtGVddjsyJ

• Dr. John Cush

Delay in PsA diagnosis Meta Analysis of 32000+ pts Median diagnostic delay 2.5 years Median delay in referral 1 year Increase odds of Rx damage from 50% Geographic variation We need to do better #ACR25 @RheumNow #ABSTRACT1713 https://t.co/CWwqosa5NT

• https://x.com/AurelieRheumo/status/1982914302769328269/photo/1
• https://x.com/AurelieRheumo/status/1982914302769328269/photo/1

PMR patients need healthcare professionals who know a bit about their disease. Survey of US HCPs, amongst responders: - 68% were not aware/unsure about PMR - of those who were aware, knowledge was… not great (see below) PMR needs everyone’s respect #ACR25 ABST1617 @RheumNow https://t.co/SpyEnAW8lI

• https://x.com/drdavidliew/status/1982916905532108871/photo/1

A largely understudied area: Impact of peri-menopause in PsA Toronto Cohort 473pts, HRT 1.5% Peri menopause = increase DAPSA, TJC, SJC, FACIT-fatigue, HAQ compared to pre- and post-menopause No association w/ BMI, but with fatigue Less impact when education level increases https://t.co/bSuGxZCbGn

• https://x.com/AurelieRheumo/status/1982918433344819438/photo/1
• https://x.com/AurelieRheumo/status/1982918433344819438/photo/1
• https://x.com/AurelieRheumo/status/1982918433344819438/photo/1

“The true master clinicians I know have an exceptional tolerance for uncertainty” - @LCalabreseDO, #ACR25 (Gary Hoffman and Carol Langford got a specific name check there too) ‘Fake Rheum: Case-Based Approach to Rheumatology Mimics” @CCalabreseDO @RheumNow https://t.co/VkKXoMn1Ls

• https://x.com/drdavidliew/status/1982920392680632803/photo/1

Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE Compared to non-SLE pts, those with SLE receiving ICIs had: 🔹 ↑ risk of thrombocytopenia & pancytopenia 🔹 No significant difference in all-cause mortality @RheumNow #ACR25 https://t.co/N1iOvxbsAZ

• https://x.com/AkhilSoodMD/status/1982921999350718964/photo/1

IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo

• https://x.com/Dr_Brian_MD/status/1982922182314561831/photo/1

The first father-daughter session at ACR? Brilliant session in diagnostic thinking and mimics in rheumatology from @LCalabreseDO and @CCalabreseDO, teasing apart heuristics, biases, and examples straddling the ID-Rheum divide. Well worth catching on the replay #ACR25 @RheumNow https://t.co/16FEqVyDGg

• https://x.com/drdavidliew/status/1982922331971563869/photo/1
• https://x.com/drdavidliew/status/1982922331971563869/photo/1
• https://x.com/drdavidliew/status/1982922331971563869/photo/1

ANCA status does not inform IL-5 agent response in EGPA patients Terrier et al. analyzed the OLE of MANDARA and compared ANCA+ and ANCA- subgroups: - similar rates of remission - similar rates of GC withdrawal - comparable relapse rates @RheumNow #ACR25 Abst 1594